ストックスクリーナーアプリを入手
83.45
0.82%
-0.69
前日終値:
$84.14
開ける：
$84.54
24時間の取引高:
927.84K
Relative Volume:
1.72
時価総額：
$8.85B
収益：
$612.78M
当期純損益:
$-86.37M
株価収益率:
-51.83
EPS:
-1.61
ネットキャッシュフロー:
$-62.91M
1週間 パフォーマンス:
+0.51%
1か月 パフォーマンス:
-2.56%
6か月 パフォーマンス:
+10.46%
1年 パフォーマンス:
+27.83%
1日の値動き範囲:
$82.76
$85.03
1週間の範囲:
$82.19
$89.12
52週間の値動き範囲:
$62.78
$93.45
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
名前
Intra Cellular Therapies Inc
セクター
電話
(646) 440-9333
住所
135 ROUTE 202/206, BEDMINSTER, NY
ITCI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
83.45 | 8.85B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-11 | 開始されました | TD Cowen | Outperform |
| 2023-04-20 | 開始されました | Morgan Stanley | Overweight |
| 2022-08-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-14 | 開始されました | UBS | Buy |
| 2022-04-22 | 開始されました | Piper Sandler | Neutral |
| 2022-02-16 | 開始されました | Goldman | Buy |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2020-12-15 | 開始されました | BofA Securities | Buy |
| 2020-12-10 | 開始されました | Goldman | Buy |
| 2020-02-20 | 開始されました | Evercore ISI | Outperform |
| 2020-01-31 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-12-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-12 | 開始されました | Jefferies | Buy |
| 2018-02-26 | 開始されました | JP Morgan | Overweight |
| 2018-02-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-11-08 | アップグレード | SunTrust | Hold → Buy |
| 2017-09-07 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-09-29 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-09-29 | ダウングレード | SunTrust | Buy → Neutral |
すべてを表示
Intra Cellular Therapies Inc (ITCI) 最新ニュース
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges - Investing.com India
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges By Investing.com - Investing.com South Africa
Geode Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Intra-Cellular Therapies, Avantor Lag - Barron's
Franklin Resources Inc. Purchases 155,655 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
State Street Corp Has $136.02 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Y Intercept Hong Kong Ltd Trims Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies' SWOT analysis: Caplyta's success drives stock potential - Investing.com
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - The Manila Times
Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College - EIN News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Wellington Management Group LLP - MarketBeat
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Insider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 51,000 Shares of Stock - MarketBeat
Intra-cellular Therapies CEO sells $8.72 million in stock By Investing.com - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 11,104 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD - MSN
Study Estimates 5 Million People Could Benefit from Magic Mushrooms for Depression Treatment - Managed Healthcare Executive
(ITCI) Investment Analysis and Advice - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of Montreal Can - MarketBeat
Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term - Simply Wall St
HighVista Strategies LLC Has $548,000 Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 23,400 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Additional Treatment for Depression - Managed Healthcare Executive
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar - BioSpace
Intra-Cellular Ther (ITCI-Q) QuotePress Release - The Globe and Mail
Point72 Hong Kong Ltd Sells 38,075 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - The Manila Times
Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
54,629 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Edgestream Partners L.P. - MarketBeat
Cerity Partners LLC Has $3.23 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies stock rated Outperform by Mizuho, with 13% stock rise post-earnings - Investing.com UK
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? - Yahoo Finance
Vestal Point Capital LP Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Suvretta Capital Management LLC Has $105.29 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Decreased by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 116,146 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
How Intra-Cellular surprised Wall Street by breaking character - BioPharma Dive
Cynosure Group LLC Purchases 8,909 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Algert Global LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Natixis Advisors LLC Has $1.80 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $97.23 - MarketBeat
Intra Cellular Therapies Inc (ITCI) 財務データ
収益
当期純利益
現金流量
EPS
Intra Cellular Therapies Inc (ITCI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
2.89%
1.65%
大文字化:
|
ボリューム (24 時間):